TIRZEPATIDE 30mg
TIRZEPATIDE 30mg
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists[3][4].
- Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
| Phase | Weekly Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 units (0.25 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 50 units (0.50 mL) × 1 injection |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) × 1 injection |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 1 injection |
Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. All doses fit in a single 1 mL insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.
